AN AUTHORITATIVE RESOURCE FOR EVERYTHING ABOUT CANCER
Cancer Education
Explore expert insights on the fundamentals of cancer, including how it develops, key risk factors, prevention strategies, and treatment options. This section also highlights cancer awareness months and related observance days and weeks. Commentaries from our network of oncology professionals shed light on critical issues that require greater attention across the cancer care and research continuum.
Dr. Vivian G Oehler on Advances in Myeloproliferative Neoplasm Treatment
By The Cancer News Team
Dr. Vivian G. Oehler reviews major advances in myeloproliferative neoplasms, including pelabresib in myelofibrosis, CALR-targeted therapy in essential thrombocythemia, rusfertide in polycythemia vera, and new allosteric inhibitors in CML.
Dr. Vivian G Oehler on Advances in Myeloproliferative Neoplasm Treatment
By The Cancer News Team
Dr. Vivian G. Oehler reviews major advances in myeloproliferative neoplasms, including pelabresib in myelofibrosis, CALR-targeted therapy in essential thrombocythemia, rusfertide in polycythemia vera, and new allosteric inhibitors in CML.
Dr. Vivian G Oehler on Advances in Myeloproliferative Neoplasm Treatment
By The Cancer News Team
Dr. Vivian G. Oehler reviews major advances in myeloproliferative neoplasms, including pelabresib in myelofibrosis, CALR-targeted therapy in essential thrombocythemia, rusfertide in polycythemia vera, and new allosteric inhibitors in CML.
Dr. Ryan Cassaday on Recent Advances in the Treatment of Acute Lymphoblastic Leukemia
By The Cancer News Team
Dr. Ryan Cassaday reviews chemotherapy-free frontline strategies, MRD risk stratification, CAR T-cell consolidation, and transplant decision-making in adult acute lymphoblastic leukemia (ALL).
Dr. Ryan Cassaday on Recent Advances in the Treatment of Acute Lymphoblastic Leukemia
By The Cancer News Team
Dr. Ryan Cassaday reviews chemotherapy-free frontline strategies, MRD risk stratification, CAR T-cell consolidation, and transplant decision-making in adult acute lymphoblastic leukemia (ALL).
Dr. Ryan Cassaday on Recent Advances in the Treatment of Acute Lymphoblastic Leukemia
By The Cancer News Team
Dr. Ryan Cassaday reviews chemotherapy-free frontline strategies, MRD risk stratification, CAR T-cell consolidation, and transplant decision-making in adult acute lymphoblastic leukemia (ALL).
Dr. Mwanasha Hamuza Merrill on Frontline and Emerging Treatment Strategies for Chronic Lymphocytic Leukemia
By The Cancer News Team
At Best of Hematology & Breast Cancer 2026, Dr. Mwanasha Hamuza Merrill reviews frontline and emerging treatment strategies for chronic lymphocytic leukemia, highlighting CLL17, BRUIN 314, and novel BTK degrader data.
Dr. Mwanasha Hamuza Merrill on Frontline and Emerging Treatment Strategies for Chronic Lymphocytic Leukemia
By The Cancer News Team
At Best of Hematology & Breast Cancer 2026, Dr. Mwanasha Hamuza Merrill reviews frontline and emerging treatment strategies for chronic lymphocytic leukemia, highlighting CLL17, BRUIN 314, and novel BTK degrader data.
Dr. Mwanasha Hamuza Merrill on Frontline and Emerging Treatment Strategies for Chronic Lymphocytic Leukemia
By The Cancer News Team
At Best of Hematology & Breast Cancer 2026, Dr. Mwanasha Hamuza Merrill reviews frontline and emerging treatment strategies for chronic lymphocytic leukemia, highlighting CLL17, BRUIN 314, and novel BTK degrader data.
Dr. Ning Dong on Clinical Updates on Classification, Treatment, and Emerging Trials of T-Cell Lymphoma
By The Cancer News Team
Dr. Ning Dong reviews updated WHO classification, frontline and relapsed treatment strategies, prognostic modeling in advanced cutaneous T-cell lymphoma, and promising phase 2 trials including CD5 CAR T therapy.
Dr. Ning Dong on Clinical Updates on Classification, Treatment, and Emerging Trials of T-Cell Lymphoma
By The Cancer News Team
Dr. Ning Dong reviews updated WHO classification, frontline and relapsed treatment strategies, prognostic modeling in advanced cutaneous T-cell lymphoma, and promising phase 2 trials including CD5 CAR T therapy.
Dr. Ning Dong on Clinical Updates on Classification, Treatment, and Emerging Trials of T-Cell Lymphoma
By The Cancer News Team
Dr. Ning Dong reviews updated WHO classification, frontline and relapsed treatment strategies, prognostic modeling in advanced cutaneous T-cell lymphoma, and promising phase 2 trials including CD5 CAR T therapy.
Dr. Sioban B. Keel on Germline Cancer Predisposition in Myeloid Malignancies
By The Cancer News Team
Dr. Sioban B. Keel reviews germline cancer predisposition in myeloid malignancies, highlighting DDX41, donor selection, somatic mosaicism, and how inherited risk reshapes diagnosis, monitoring, and transplant decisions.
Dr. Sioban B. Keel on Germline Cancer Predisposition in Myeloid Malignancies
By The Cancer News Team
Dr. Sioban B. Keel reviews germline cancer predisposition in myeloid malignancies, highlighting DDX41, donor selection, somatic mosaicism, and how inherited risk reshapes diagnosis, monitoring, and transplant decisions.
Dr. Sioban B. Keel on Germline Cancer Predisposition in Myeloid Malignancies
By The Cancer News Team
Dr. Sioban B. Keel reviews germline cancer predisposition in myeloid malignancies, highlighting DDX41, donor selection, somatic mosaicism, and how inherited risk reshapes diagnosis, monitoring, and transplant decisions.
Dr. L. Christine Fang on Modern De-Escalation in Breast Cancer Radiation Therapy
By The Cancer News Team
Dr. L. Christine Fang reviews modern de-escalation strategies in breast cancer radiation therapy, including hypofractionation, partial breast irradiation, and radiation omission for selected patients.
Dr. L. Christine Fang on Modern De-Escalation in Breast Cancer Radiation Therapy
By The Cancer News Team
Dr. L. Christine Fang reviews modern de-escalation strategies in breast cancer radiation therapy, including hypofractionation, partial breast irradiation, and radiation omission for selected patients.
Dr. L. Christine Fang on Modern De-Escalation in Breast Cancer Radiation Therapy
By The Cancer News Team
Dr. L. Christine Fang reviews modern de-escalation strategies in breast cancer radiation therapy, including hypofractionation, partial breast irradiation, and radiation omission for selected patients.
Dr. Brie Chun on Who Really Needs More Adjuvant Therapy in Early-Stage Breast Cancer?
By The Cancer News Team
Dr. Brie Chun reviews long-term SOFT and TEXT trial data to clarify which premenopausal patients with early-stage hormone receptor–positive breast cancer benefit most from ovarian function suppression.
Dr. Brie Chun on Who Really Needs More Adjuvant Therapy in Early-Stage Breast Cancer?
By The Cancer News Team
Dr. Brie Chun reviews long-term SOFT and TEXT trial data to clarify which premenopausal patients with early-stage hormone receptor–positive breast cancer benefit most from ovarian function suppression.
Dr. Brie Chun on Who Really Needs More Adjuvant Therapy in Early-Stage Breast Cancer?
By The Cancer News Team
Dr. Brie Chun reviews long-term SOFT and TEXT trial data to clarify which premenopausal patients with early-stage hormone receptor–positive breast cancer benefit most from ovarian function suppression.
Dr. Emily N. Palmquist on De-escalation of Axillary Surgery in Early-Stage Breast Cancer
By The Cancer News Team
Dr. Emily N. Palmquist reviews evidence from SOUND, INSEMA, and BOOG trials on safely omitting sentinel lymph node biopsy in select patients with early-stage breast cancer.
Dr. Emily N. Palmquist on De-escalation of Axillary Surgery in Early-Stage Breast Cancer
By The Cancer News Team
Dr. Emily N. Palmquist reviews evidence from SOUND, INSEMA, and BOOG trials on safely omitting sentinel lymph node biopsy in select patients with early-stage breast cancer.
Dr. Emily N. Palmquist on De-escalation of Axillary Surgery in Early-Stage Breast Cancer
By The Cancer News Team
Dr. Emily N. Palmquist reviews evidence from SOUND, INSEMA, and BOOG trials on safely omitting sentinel lymph node biopsy in select patients with early-stage breast cancer.
Dr. Chaitra S. Ujjani on B-Cell Lymphoma: Bispecific Antibodies and CAR T-Cell Therapy Updates from ASH
By The Cancer News Team
Expert highlights from Dr. Chaitra S. Ujjani on bispecific antibodies and CAR T-cell therapy in B-cell lymphomas, featuring key efficacy, safety, and practice-changing updates from the 2025 ASH meeting.
Dr. Chaitra S. Ujjani on B-Cell Lymphoma: Bispecific Antibodies and CAR T-Cell Therapy Updates from ASH
By The Cancer News Team
Expert highlights from Dr. Chaitra S. Ujjani on bispecific antibodies and CAR T-cell therapy in B-cell lymphomas, featuring key efficacy, safety, and practice-changing updates from the 2025 ASH meeting.
Dr. Chaitra S. Ujjani on B-Cell Lymphoma: Bispecific Antibodies and CAR T-Cell Therapy Updates from ASH
By The Cancer News Team
Expert highlights from Dr. Chaitra S. Ujjani on bispecific antibodies and CAR T-cell therapy in B-cell lymphomas, featuring key efficacy, safety, and practice-changing updates from the 2025 ASH meeting.
Dr. Ghulam Rehman Mohyuddin on Relapsed/Recurrent Multiple Myeloma: CAR T-Cell Therapy and Bispecific Antibody Strategies
By The Cancer News Team
Dr. Ghulam Rehman Mohyuddin reviews modern treatment strategies for relapsed multiple myeloma, comparing CAR T-cell therapy and bispecific antibodies, with practical guidance on sequencing and patient selection.
Dr. Ghulam Rehman Mohyuddin on Relapsed/Recurrent Multiple Myeloma: CAR T-Cell Therapy and Bispecific Antibody Strategies
By The Cancer News Team
Dr. Ghulam Rehman Mohyuddin reviews modern treatment strategies for relapsed multiple myeloma, comparing CAR T-cell therapy and bispecific antibodies, with practical guidance on sequencing and patient selection.
Dr. Ghulam Rehman Mohyuddin on Relapsed/Recurrent Multiple Myeloma: CAR T-Cell Therapy and Bispecific Antibody Strategies
By The Cancer News Team
Dr. Ghulam Rehman Mohyuddin reviews modern treatment strategies for relapsed multiple myeloma, comparing CAR T-cell therapy and bispecific antibodies, with practical guidance on sequencing and patient selection.